Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
Gastric cancer (GC) is one of the most common malignancies. According to the global cancer
statistics 2018, there were 1,033,701 new cases of gastric cancer per year, ranked the fifth
place in new tumors, and 782,685 deaths, ranked the second place in cancer deaths. At
present, surgery is the only way to cure gastric cancer, but the 5-year survival rate is only
20%-30%. studies have confirmed that neoadjuvant therapy could improve the R0 resection rate
and overall survival, which is considered a better treatment strategy.
PD 1 monoclonal antibody is definitely effective in neoadjuvant therapy in other tumors such
as NSCLC and bladder cancer, especially in PD-L1+ patients. However, there is no research of
PD-1 monoclonal antibody in neoadjuvant therapy of gastric cancer. Thus we plan to conduct
this prospective phase II clinical trial, evaluating the safety and efficacy of toripalimab,
also known as JS001, in combination with XELOX for the neoadjuvant therapy of gastric cancer.